Do you want to link to this Other Site and leave

YOU ARE NOW LEAVING AMGEN KOREA'S WEB SITE. Amgen Korea takes takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Notification according to label change order _[Repatha Inj. Pre-filled syringe (evolocumab) and 1 other]

In accordance with the results of the drug re-examination, the Ministry of Food and Drug Safety’s Label Change Order (Biopharmaceutical Quality Management Division-155, 2024.02.16) has changed the precautions for the use of the following products.

As a result, we would like to inform you that the product information for this product has been changed as of May 16, 2024.

  • Product: Repatha Inj. Pre-filled syringe (evolocumab) and Repatha Inj. Pre-filled pen (evolocumab)
  • Changes: Precautions for Use [3. Adverse Reactions, Post-marketing surveillance results in Korea]
  • Label change date: May 16, 2024 (3 months after MFDS’s instruction date)
  • Attachments: Ministry of Food and Drug Safety Label Change Order official letter, Changes, and comparative table [Please refer to our Korean website( ]  

For more information, please refer to the revised product information (date of revision: May 16, 2024) attached to the product, and you can also check the product information on our website (